Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant
Stephen Gough Novo Nordisk

Novo Nordisk has appointed Stephen Gough as senior principal clinical scientist. 

Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to phase III and beyond for obesity and diabetes.

He joins from the Oxford Centre for Diabetes Endocrinology and Metabolism, where he worked with research groups focusing on autoimmunity.

He said: “I am excited to join a company with over 90 years of dedication to finding better treatments for diabetes. 

“I look forward to working with the exceptional scientific team at Novo Nordisk to help translate research into meaningful therapies that makes a difference for patients.”

Alan Moses, CMO of Novo Nordisk, added: “With [Gough's] key clinical expertise, his experience as a researcher focused on patient issues, and his compassion for patients with diabetes, Professor Gough will have a vital role in working toward Novo Nordisk's ambition of changing diabetes.”

1st October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics